BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Korea-based ST Pharm takes leap towards world's largest oligonucleotide CDMO

November 30, 2021 | News

The company will be investing $126 million in total



ST Pharm Co. Ltd., an Active Pharmaceutical Ingredient (API) contract development and manufacturing organization (CDMO) in Republic of Korea, has announced to build the second oligonucleotide manufacturing plant for an expansion of production facilities and to preoccupy the rapidly growing oligonucleotide therapeutics market.

ST Pharm will invest in total $126 million at Banwol campus located in Ansan until 2025 and this will construct the second oligonucleotide plant with four to six large production lines.

The second oligonucleotide manufacturing plant will be designed to maximise efficiency by shortening the production period through a parallel cross-production process design. In addition, ST Pharm will be installing a solvent recycling system for cost reduction and to make eco-friendly manufacturing process.

In 2018, ST Pharm has established its first oligonucleotide plant at Banwol campus and this had a production capacity of 1.5 mole per year. In 2020, ST Pharm has decided to retrofit the plant for further capacity expansion and when completed, ST Pharm will have a production capacity of 6.4 mole per year.

Furthermore, the establishment of the second oligonucleotide plant will provide a production capacity of 14 mole per year, which forecasts ST Pharm to become the world's largest leading CDMO in oligonucleotide production in 2025, in terms of capacity.